发明授权
US08268773B2 Methods of treating multiple sclerosis (MS) using an IL-17A and IL-17F antagonist
有权
使用IL-17A和IL-17F拮抗剂治疗多发性硬化（MS）的方法
- 专利标题： Methods of treating multiple sclerosis (MS) using an IL-17A and IL-17F antagonist
- 专利标题（中）： 使用IL-17A和IL-17F拮抗剂治疗多发性硬化（MS）的方法
-
申请号： US13015304申请日： 2011-01-27
-
公开(公告)号： US08268773B2公开(公告)日： 2012-09-18
- 发明人: Scott R. Presnell , Steven K. Burkhead , Steven D. Levin , Rolf E. Kuestner , Zeren Gao , Stephen R. Jaspers , Janine Bilsborough
- 申请人： Scott R. Presnell , Steven K. Burkhead , Steven D. Levin , Rolf E. Kuestner , Zeren Gao , Stephen R. Jaspers , Janine Bilsborough
- 申请人地址： US WA Seattle
- 专利权人： ZymoGenetics, Inc.
- 当前专利权人： ZymoGenetics, Inc.
- 当前专利权人地址： US WA Seattle
- 代理机构： Nelson Mullins Riley & Scarborough LLP
- 代理商 Jane E. Remillard, Esq.; Jill Gorny Sloper, Esq.
- 主分类号： A61K38/00
- IPC分类号： A61K38/00
摘要：
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.
公开/授权文献
信息查询
IPC分类:
